BridgeBio Pharma, Inc.
At today's price, BridgeBio Pharma, Inc. (BBIO) is priced for today's economics sustained for ~20.9 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• BridgeBio's story is now one drug: Attruby (acoramidis) for the heart condition ATTR-CM, which generated $362.4 million in its first full year on the market and $180.6 million of U.S. net product revenue in the first quarter of 2026 alone [Source: BridgeBio FY2025 and Q1 2026 results]. • The biggest risk is competition for the same patients: Attruby launched into a market dominated by Pfizer's tafamidis and now facing Alnylam's Amvuttra, so the bet is on how much share a newer entrant can take
Is BBIO overvalued? See what's priced in →
441 institutional managers reported holding BBIO in 13F filings for the quarter ended 2026-03-31. 78 opened new positions that quarter. Held by Vanguard Group, BlackRock, KKR, among others. On the short side, 25.4M shares were sold short as of the 2026-06-15 count, about 13% of shares outstanding (8.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BBIO's share count grew 32.7% over the past five years even with $275.47M spent on repurchases. It pays no dividend. Cash returned over the past three years: $130.78M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at BBIO over the trailing three years. Absence is a fact about the company, not a signal. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BBIO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-05 | -5.0% | +23.5% |
| 2023-08-04 | -2.3% | -19.2% |
| 2023-11-03 | +8.2% | +30.7% |
| 2024-05-03 | +3.0% | -7.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BBIO's latest 8-K filings: 2026-07-02 (items 1.01, 3.02, 3.03, 5.03, 7.01, 9.01); 2026-06-26 (items 5.02, 5.07, 9.01); 2026-05-27 (items 8.01, 9.01); 2026-05-13 (items 8.01, 9.01); 2026-05-08 (items 1.01, 1.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.